Istari reports Phase I survival data for glioblastoma candidate

Istari Oncology Inc. (Research Triangle Park, N.C.) reported data from 61 patients with recurrent glioblastoma in a Phase I trial showing that Pvsripo led to a median overall survival (OS) of 12.5 months vs. 11.3 months for matched historical controls. The OS rate at both 12 and 24 months was 21% compared with 14% and 4%, respectively, for historical controls. Data were published in the New England Journal of Medicine. The open-label, dose-escalation, U.S. trial was sponsored by Duke University in collaboration with Istari and NCI.

A Phase II trial is evaluating Pvsripo alone and in combination with chemotherapy to treat recurrent glioblastoma...